Neumora Therapeutics Scraps Lead Asset Navacaprant After Study Failures

Dow Jones

Jun 15

By Colin Kellaher

Neumora Therapeutics is throwing in the towel on navacaprant following the failure of its lead drug candidate in a pair of late-stage studies.

Neumora on Monday said navacaprant didn't achieve statistical significance on the primary or key secondary endpoints in two Phase 3 studies in major depressive disorder.

The Watertown, Mass., clinical-stage biopharmaceutical company said it plans to slash 35% of its workforce as it focuses on advancing the rest of its portfolio.

Neumora said it expects the job cuts to result in $10 million of annual savings, adding that its current cash and equivalents provide a runway into the third quarter of 2027.

Trading in shares of Neumora, which closed Friday at $1.78, was halted premarket on Monday.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

June 15, 2026 08:40 ET (12:40 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2643205965"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2643205965\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2643205965?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 20:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643205965","market":"us","top_or_hot":-1,"title":"Neumora Therapeutics Scraps Lead Asset Navacaprant After Study Failures","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> is throwing in the towel on navacaprant following the failure of its lead drug candidate in a pair of late-stage studies. \n</p>\n<p>\n  Neumora on Monday said navacaprant didn't achieve statistical significance on the primary or key secondary endpoints in two Phase 3 studies in major depressive disorder. \n</p>\n<p>\n  The Watertown, Mass., clinical-stage biopharmaceutical company said it plans to slash 35% of its workforce as it focuses on advancing the rest of its portfolio. \n</p>\n<p>\n  Neumora said it expects the job cuts to result in $10 million of annual savings, adding that its current cash and equivalents provide a runway into the third quarter of 2027. \n</p>\n<p>\n  Trading in shares of Neumora, which closed Friday at $1.78, was halted premarket on Monday. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 15, 2026 08:40 ET (12:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neumora Therapeutics Scraps Lead Asset Navacaprant After Study Failures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeumora Therapeutics Scraps Lead Asset Navacaprant After Study Failures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-15 20:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> is throwing in the towel on navacaprant following the failure of its lead drug candidate in a pair of late-stage studies. \n</p>\n<p>\n  Neumora on Monday said navacaprant didn't achieve statistical significance on the primary or key secondary endpoints in two Phase 3 studies in major depressive disorder. \n</p>\n<p>\n  The Watertown, Mass., clinical-stage biopharmaceutical company said it plans to slash 35% of its workforce as it focuses on advancing the rest of its portfolio. \n</p>\n<p>\n  Neumora said it expects the job cuts to result in $10 million of annual savings, adding that its current cash and equivalents provide a runway into the third quarter of 2027. \n</p>\n<p>\n  Trading in shares of Neumora, which closed Friday at $1.78, was halted premarket on Monday. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 15, 2026 08:40 ET (12:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NMRA","symbol_name":"Neumora Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2643205965","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643205965","pubTimestamp":1781527200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Neumora Therapeutics is throwing in the towel on navacaprant following the failure of its lead drug candidate in a pair of late-stage studies.Neumora on Monday said navacaprant didn't achieve statistical significance on the primary or key secondary endpoints in two Phase 3 studies in major depressive disorder.The Watertown, Mass., clinical-stage biopharmaceutical company said it plans to slash 35% of its workforce as it focuses on advancing the rest of its portfolio.Neumora said it expects the job cuts to result in $10 million of annual savings, adding that its current cash and equivalents provide a runway into the third quarter of 2027.Trading in shares of Neumora, which closed Friday at $1.78, was halted premarket on Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NMRA":"Neumora Therapeutics, Inc.","BK4007":"制药","DBB":"基础金属ETF-PowerShares"},"translate_title":"Neumora Therapeutics在研究失败后废弃主要资产Navacaprant","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NMRA":1.5,"DBB":1.5},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Neumora Therapeutics is throwing in the towel on navacaprant following the failure of its lead drug candidate in a pair of late-stage studies. \n\n\n  Neumora on Monday said navacaprant didn't achieve statistical significance on the primary or key secondary endpoints in two Phase 3 studies in major depressive disorder. \n\n\n  The Watertown, Mass., clinical-stage biopharmaceutical company said it plans to slash 35% of its workforce as it focuses on advancing the rest of its portfolio. \n\n\n  Neumora said it expects the job cuts to result in $10 million of annual savings, adding that its current cash and equivalents provide a runway into the third quarter of 2027. \n\n\n  Trading in shares of Neumora, which closed Friday at $1.78, was halted premarket on Monday. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 15, 2026 08:40 ET (12:40 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}